This move is archived. Current quotes and coverage live on the stock page.
Follow HBP
Helix BioPharma Corp. faced a notable decline, closing down nearly 5% in the latest trading session.
In the most recent trading session, Helix BioPharma Corp. (HBP.TO) saw its stock price drop by 4.86%, closing at CA$1.37. This decline raises concerns among investors about the company's financial health and market positioning, especially given the lack of recent positive news to support its stock price.
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$68.74M
52W high
$2.60
52W low
$0.82
1W change
-7.07%
Beta
-0.14
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 177.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+177.8% Upside
Current Price
C$0.90
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
111.5%
Annualized
90-Day Vol
89.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.75
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.85 | C$0.58 – C$1.25 |
| 60 trading days | C$0.80 | C$0.46 – C$1.38 |
| 90 trading days | C$0.75 | C$0.39 – C$1.47 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor Helix BioPharma's financial performance and market developments, especially in light of its recent losses and the absence of significant corporate news to buoy investor confidence.
Helix BioPharma Corp. down 4.86% in one trading day
The market cap now stands at CA$109.6 million, reflecting investor concerns over the company's financial trajectory.
Bull case
If Helix BioPharma can successfully navigate its ongoing fundraising efforts and attract institutional investment, it might regain investor confidence and see a rebound in its stock price.
Bear case
Continued losses and a lack of positive news could further erode investor confidence, leading to additional declines in the stock price and potential challenges in securing necessary funding.
Recent Performance Overview
Helix BioPharma Corp.'s stock price fell by 4.86% in the last trading session, closing at CA$1.37. This performance is part of a broader trend of volatility for the company, which has struggled to maintain investor interest amid ongoing financial challenges.
Lack of Positive News
Despite the recent filing of interim financial statements, there has been no significant news to drive investor confidence. The absence of positive developments or strategic announcements could be contributing to the stock's downward trajectory.
Looking Ahead
Investors are advised to keep an eye on Helix BioPharma's upcoming financial results and any potential news regarding its fundraising efforts. The company's ability to secure institutional investment and make progress toward a NASDAQ uplisting will be crucial for its recovery.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
